Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 12/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12567532 | 0.87 | THRB (0.45) | THRBITGB3ITGA2BALDH1A1CYP3A4 | |
| SCHEMBL12567540 | 0.85 | THRB (0.48) | THRBFFAR1ALDH1A1CYP3A4TSHR | |
| SCHEMBL12567461 | 0.84 | HTT (0.43) | THRBALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL20110404 | 0.83 | MAPT (0.44) | THRBAKR1C3 | |
| SCHEMBL12567464 | 0.83 | CYP3A4 (0.47) | THRBALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL19024612 | 0.82 | THRB (0.42) | THRBFFAR1ALDH1A1CYP3A4TSHR | |
| SCHEMBL28678530 | 0.82 | THRB (0.42) | THRBFFAR1ALDH1A1CYP3A4TSHR | |
| SCHEMBL8914045 | 0.82 | HTT (0.40) | THRBALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL8913467 | 0.82 | HTT (0.40) | THRBALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL8914125 | 0.82 | HTT (0.40) | THRBALDH1A1CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8425988-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition and anisotropic polymer | JNC CORPORATION (JP) | 2013-04-23 | — | — | US | disclosed |
| US-20110147657-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND ANISOTROPIC POLYMER | CHISSO CORPORATION (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110147657-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND ANISOTROPIC POLYMER | SSB, LEF1, UACA | THRB 4550/4885AKR1C3 1983/4885FFAR1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.